commercial program grafit (ERITHACUS SOFTWARE LIMITED)
90
Structured Review
ERITHACUS SOFTWARE LIMITED
commercial program grafit
Commercial Program Grafit, supplied by ERITHACUS SOFTWARE LIMITED, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/commercial+program+grafit/commercial+program+grafit/pmc03757138-111-10-12
Average 90 stars, based on 1 article reviews
Commercial Program Grafit, supplied by ERITHACUS SOFTWARE LIMITED, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/commercial+program+grafit/commercial+program+grafit/pmc03757138-111-10-12
Average 90 stars, based on 1 article reviews
commercial program grafit - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
other:Article Title: A 1 R-A 2A R heteromers coupled to G s and G i/0 proteins modulate GABA transport into astrocytes Article Snippet: Radioligand displacement curves were analyzed by nonlinear regression using commercial Article Title: Modulation of GABA Transport by Adenosine A1R-A2AR Heteromers, Which Are Coupled to Both Gs- and Gi/o-Proteins Article Snippet: Radioligand displacement curves were analyzed by nonlinear regression using commercial Article Title: Modulation of GABA Transport by Adenosine A 1 R–A 2A R Heteromers, Which Are Coupled to Both G s - and G i/o -Proteins Article Snippet: Radioligand displacement curves were analyzed by nonlinear regression using commercial Binding Assay:Article Title: Novel ergopeptides as dual ligands for adenosine and dopamine receptors. Article Snippet: Multivalent ligands are promising pharmacological tools that may be more efficacious for several diseases than highly selective single-target drugs.. A combined therapy using dopaminergic agonists and adenosinergic antagonists is currently being evaluated for the treatment of Parkinson’s disease.. [(a) Kanda, T.; et al. Exp. Article Title: Indoloquinolizidine-peptide hybrids as multiple agonists for D1 and D2 dopamine receptors. Article Snippet: Multi-target ligand approaches constitute a new trend in pharmacological research, with potential applications in disorders for which the alteration of a single receptor is insufficient to elicit the desired therapeutic effect.. The development of ligands that simultaneously activate different dopamine receptor subtypes is one of the most successful therapeutic approaches for the treatment of Parkinson’s disease (PD).. 3] However, with the exception of levodopa, most multiple dopamine agonists in current use interact at D2 dopamine receptors (D2R) and D3 dopamine receptors (D3R), but bind poorly to the D1 dopamine receptor (D1R) subtype, a known target for antiparkinsonian agents. Article Title: Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1-A2A Receptor Heteromers Article Snippet: .. Radioligand displacement curves were analyzed by nonlinear regression using commercial Article Title: Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A 1 –A 2A Receptor Heteromers Article Snippet: .. Radioligand displacement curves were analyzed by nonlinear regression using commercial |